COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 704: Articles 7031-7040  | Next

The influence of place on COVID-19 vaccine coverage in Alberta: A multilevel analysis
Paudel, Y. R., Du, C., MacDonald, S. E.
10.1101/2022.06.15.22276467 — Posted: 2022-06-16
Cycle threshold values in symptomatic COVID-19 cases in England
Funk, S., Abbott, S.
10.1101/2022.06.13.22276321 — Posted: 2022-06-16
COVID-19 Vaccine Hesitancy and Confidence in the Philippines and Malaysia: A Cross-sectional Study of Sociodemographic Factors and Information-Seeking
Brackstone, K., Marzo, R. R., Bahari, R., Head, M. G., Patalinghug, M. E., Su, T. T.
10.1101/2022.06.15.22276457 — Posted: 2022-06-16
Prevalence of COVID-19 and Long COVID in Collegiate Student Athletes from Spring 2020 to Fall 2021: A Retrospective Survey
Massey, D., Saydah, S., Adamson, B., Lincoln, A., Aukerman, D., Berke, E., Sikka, R., Krumholz, H.
10.1101/2022.06.12.22276048 — Posted: 2022-06-16
Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era
Ioannou, G. N., Bohnert, A. S. B., O'Hare, A. M., Boyko, E. J., Smith, V. A., Maciejewski, M. L., Bowling, C. B., Viglianti, E., Iwashyna, T. J., Hynes, D. M., Berry, K., COVID-19 Observational Research Collaboratory (CORC)
10.1101/2022.06.15.22276466 — Posted: 2022-06-16
Efficacy and Safety of Nebulized Ethanol Inhalation in COVID-19 Treatment. A Randomized, Clinical Trial
Amoushahi, A., Moazam, E., Reza Tabatabaei, A., Ghasimi, G., Salvatori, P., Grant-Whyte, I., Ragab Ezz, A.
10.1101/2022.06.15.22276427 — Posted: 2022-06-16
Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
Miyamoto, S., Arashiro, T., Ueno, A., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., Ozono, S., Hemmi, T., Hirata, Y., Moriyama, S., Kotaki, R., Kinoshita, H., Yamada, S., Shinkai, M., Fukushi, S., Takahashi, Y., Suzuki, T.
10.1101/2022.06.15.22276432 — Posted: 2022-06-16
Comparison of RT-qPCR and Digital PCR Methods for Wastewater-Based Testing of SARS-CoV-2
Hinkle, A., Greenwald, H. D., Metzger, M., Thornton, M., Kennedy, L. C., Loomis, K., Herrera, M., Abayan, R.-J., Nelson, K. L., Kantor, R. S.
10.1101/2022.06.15.22276459 — Posted: 2022-06-16
The effect of altruism on COVID-19 vaccination rates
Hierro, L. A., Patino, D., Atienza, P., Garzon, A. J., Cantarero, D.
10.1101/2022.06.15.22276430 — Posted: 2022-06-16
How acceptable is rapid whole genome sequencing for infectious disease management in hospitals? Perspectives of those involved in managing nosocomial SARS-CoV-2
Flowers, P., McLeod, J., Mapp, F., Stirrup, O., Blackstone, J., Snell, L., Peters, C., Thomson, E. C., Holmes, A., Price, J. R., Partridge, D., Shallcross, L., de Silva, T., Breuer, J.
10.1101/2022.06.15.22276423 — Posted: 2022-06-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).